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Malaria is globally the most lethal parasitic disease. With an annual number of new cases 
reaching hundreds of millions and a mortality of circa 800.000 (WHO, 2010), this disease 
represents a worldwide major public health concern.  
Malaria generally occurs in tropical and subtropical areas, with most of the lethality focused 
in the African continent, particularly among children under five. The disease further 
commands a major economic impact in the Developing World estimated as a Gross Internal 
Product reduction of more than US$ 6 billion for the year 2010 alone (Sachs and Malaney, 
2002)(WHO, 2010). Such burden has significantly slowed down the social development of 
these regions in the last decades. 
Malaria is caused by an intracellular Protozoan belonging to the genus Plasmodium. P. 
falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi are the five different species able to 
infect humans (Levine, 1988)(Cox-Singh et al., 2008). P. falciparum is responsible for the most 
severe forms of the disease, and hence the near totality of the mortality. 
The parasites are transmitted through an arthropod vector, the dynamics of the disease 
being the result of a complex interplay between the human host, the parasite and its 
mosquito vector.  
2. Plasmodium falciparum – A brief reference to its life-cycle 
As a referential example, the 48-hour life cycle of P. falciparum, the major malaria pathogen – 
and the principal target of complex chemotherapeutic measures – is herein presented.  
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We assume as an arbitrary starting point the moment when a female Anopheles mosquito 
infected with P.falciparum penetrates the human skin to obtain a blood meal. If the 
mosquito saliva is infected with parasite sporozoites, these will be injected into the 
bloodstream of the host. These forms travel in the bloodstream to the liver where they 
invade hepatocytes. In this intracellular environment it rapidly divides asexually, 
generating the next life cycle stage form, the merozoites. These, following the rupture of 
the hepatocyte, are released in the bloodstream. Here, they invade erythrocytes. Once 
inside the erythrocyte, the merozoite develops towards the mature trophozoite stage. 
After these, the parasite undergoes a series of asexual divisions to produce a large 
segmented schizont filled with mono-nucleated merozoites. The erythrocyte then ruptures 
releasing the merozoites, a clinically important event associated to the characteristic 
malaria peaks of fever and chills. These merozoites swiftly reinvade new red blood cells, 
reinitiating the intra-eryrthocytic cycle. In parallel, a small proportion of merozoites take a 
new development route towards becoming sexual forms: the male and female 
gametocytes. These can reinvade the mosquito vector during its blood meal. Inside the 
mosquito, zygotes will form after meiotic events. Further development will lead to the 
formation of oocysts. These, after repeated mitotic divisions, produce a large number of 
sporozoites, which actively migrate to the salivary glands of the mosquito, ready to be 
injected into the bloodstream of a human. The cycle is hence restarted.  
3. Malaria chemotherapy 
Chemotherapy has been the mainstay for the clinical control of malaria for hundreds of 
years. Starting with the introduction of artemisinin rich teas in China 1500 years ago (Hsu, 
2009) and the use of barks containing quinine in South America in the XVII Century (Peters, 
1970), the XX Century saw the development of several synthetic and semi-synthetic 
compounds. Quinine prevailed as the major antimalarial drug used worldwide for near 300 
years, until the advent of the Second World War. The extension of this conflict drove the 
search for alternative synthetic variants. Derived from these efforts, chloroquine (CQ), a 
highly effective 4-aminoquinoline, emerged in the immediate post-War as the global 
mainstay for the treatment and control of malaria (Coatney et al., 1963). By the end of the 
1950s the next major malaria challenge emerged: P. falciparum have been able to develop 
resistance to this drug (Young and Moore, 1961). From two main foci in South East Asia and 
South America, resistance parasites invaded most of the other malaria-affected regions. In 
the late 1970s reached Africa. By the end of the Century the burden of malaria topped in a 
calculated multi-million death toll and an uncontrolled situation in large regions, 
particularly in the African Continent (Marsh, 1998).  
The severity of the situation demanded a change in concept. This came from South East Asia. 
In the late 1980s, Thailand - a region known to be a major cradle for the development of drug 
resistance – was fighting with a steep decrease of efficacy of their main national control 
programme drug, mefloquine (Nosten et al., 1991). A strategy of combining this long half-life 
drug with the fast acting/short half-life antimalarials of the artemisinin class (re-discovered in 
China during the 1970s) saved the former during the next decade (Nosten et al., 2000). 
The success of artemisinin combination therapy (ACT) in the Thai national malaria 
programme drove the rapid adoption, and progressive worldwide implementation of this 
strategy for the treatment of uncomplicated malaria. 
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This relatively new antimalaria strategy is based on the powerful pharmacodynamic action 
of the artemisinin derivatives (ARTs). These, typically artesunate or artemether, are known 
to have a Parasite Reduction Ratio of 1:10.000 (i.e., a reduction towards 0.01% of the initial 
parasitaemia in 48 hours of treatment), orders of magnitude above the typically found with 
long lasting quinoline drugs (White, 1997). This effect is short-lived, due to the characteristic 
very short half live of the ARTs, typically 20 minutes to 2-3 hours (Gautam et al., 2009). 
Upon this first impact, the long-standing partner is expected to handle more efficiently the 
remaining parasite population. The association of drugs with different expected 
mechanisms of action and associated modes of parasite resistance has been deemed as a 
strong deterrent for the development of the latter (Eastman and Fido, 2009). 
The two global main ACTs in use are artemether-lumefantrine and artesunate-amodiaquine. 
(WHO, 2010). The latter represents the main drive for this review. 
4. Amodiaquine  
Amodiaquine (AQ) emerged in the shadow of CQ success, in the late 1940s (Burckhalter et 
al., 1948). Similar to CQ, AQ has a core 4-aminoquinoline structure. Contrarily to CQ it also 
represents a Mannich base. 
AQ was never used to the same extent as CQ due to the large prevalence of the latter in the 
global malaria control programmes until the end of the XX Century. Also, its use was 
severely curtailed in the beginning of the 1990s, upon its removal from the WHO list of 
recommended antimalarials for the treatment of uncomplicated malaria (WHO, 1990). This 
decision followed the emergence of a number of clinical reports on rare (ca. 1:2000) but life-
threatening secondary events associated to its use in prophylaxis regimens among 
Caucasian travellers (Larrey et al., 1986)(Rouveix et al., 1989)(Neftel et al., 1986)(Hatton et al., 
1986). These included in most cases acute agranulocytosis, but also severe liver damage. 
During the 1990s, research - mainly based on in vitro approaches and the use of animal 
models - have pointed for the causing agent to be a toxic short lived quinone-imine (QI) 
metabolite of AQ (Jewell et al., 1995)(Tingle et al., 1995)(Naisbitt et al., 1997). The mode of 
action of this putative metabolite is still under discussion, but it is generally accepted that it 
operates by binding covalently to cell structures or/and as an hapten associated to a specific 
anti-AQ IgG antibody driven immunological response (Clarke et al., 1990). 
The described prophylaxis effects were never formally confirmed in circumstances of the 
regular treatment of uncomplicated malaria. This lack of confirmatory data has raised some 
criticisms concerning a possible over-cautious decision at WHO (Olliaro et al., 1996). In fact, 
the actual usefulness of this decision in a time when the efficacy of CQ was collapsing 
worldwide is still open to discussion. Nevertheless, AQ as a monotherapy kept being used 
in many African and South American regions for decades, both in the public and in the 
private sector. 
Interestingly, the fact that AQ has not been as intensively used as CQ possibly slowed down 
the development of parasite resistance against this drug. AQ was recovered for global use in 
the XXI Century as combination therapy partner, due its low price and capacity to handle CQ 
resistance parasites. Two combinations are available, artesunate-AQ (an ACT), and AQ-
sulfadoxine-pyrimethamine, although the latter has been recently considered to be withdrawn 
from the WHO list of recommended drugs for the treatment of uncomplicated malaria (WHO, 
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2010). Artesunate-AQ (AS-AQ) is particularly prevalent in the African continent, the epicentre 
of malaria mortality and morbidity. The combination represents the first or second line 
antimalarial treatment for uncomplicated malaria in more then twenty sub-Saharan countries 
(www.who.int/entity/malaria/am_drug_policies_by_region_afro/en/). 
AS-AQ is administrated orally in one daily dose, for three days. The present guideline is: 
4mg/Kg/day artesunate + 10mg/Kg/day AQ (WHO, 2010). Contrarily to other 
antimalarials (e.g. lumefantrine, CQ, piperaquine), the age of the patient does not seem to 
affect the plasma concentrations of AQ. The present dosing has shown to be effective in 
areas where resistance to AQ monotherapy was not widespread (<20% of the infections). In 
the event of rising resistance, changes in the formulation might be necessary, namely 
increasing the dosing in AQ. Such changes in the dosing have been applied in the past, e.g. 
with CQ (Peters, 1970) and mefloquine (Carrara et al., 2009).  
Presently, AS-AQ is available as a fixed formulation in three tablet options: 25 mg AS/67.5 
mg AQ, 50 mg AS/135 mg AQ or 100 mg AS/270 mg AQ (Coarsucam®/Winthrop®,Sanofi-
Aventis, Paris; DNDi, Geneva). 
Both AQ and desethylamodiaquine (DEAQ, AQ main active metabolite) show significant 
inter-individual variation on their pharmacokinetic parameters. AQ has a relatively short 
half-life of 4-12 hours (Giao and de Vries., 2000), being readily biotransformed in the liver 
towards DEAQ. DEAQ is a fully active antimalarial that, albeit less potent then AQ 
(Gerstner et al., 2003)(Echeverry et al., 2007) is the main responsible for the long 
pharmacodynamic effect of AQ therapy (Winstanley et al., 1990). DEAQ has a longer half-
life of 3-20 days (Hombhanje et al., 2005)(Hietala et al., 2007). Although AQ has been even 
considered as a pro-drug due to its short half-life, circumstances of extreme AQ exposure 
have been documented where this drug was detected in the urine of patients, months after 
its administration (Winstanley et al., 1987). 
AQ has been associated with both mild and severe adverse events. Mild events include 
mainly gastro-intestinal effects, particularly vomiting (Brasseur et al., 1999)(Adjuik et al., 
2002)(Cairns et al., 2010)(Nankabirwa et al., 2010) and self-reported abdominal pain (Parikh 
et al., 2007)(Bojang et al., 2010), both frequently observed in amodiaquine efficacy clinical 
trials. Most importantly, several studies have noted situations of (clinically asymptomatic) 
neutropenia upon AQ therapies in subsets of the treated population (Staedke et al., 
2001)(Adjuik et al., 2002). Although this relatively common drop in neutrophil count is not 
an exclusive effect of this drug (Nankabirwa et al., 2010), it is possibly linked with the rare 
severe adverse events observed in AQ prophylaxis. Accordingly, in this (now abandoned) 
higher dose regimens of typically 400 mg/week, the most documented serious adverse 
event was agranulocytosis (~1:2000 prevalence), followed by hepatic toxicity 
(~1:16000)(Phillips-Howard and West, 1990)(Hatton et al., 1986). 
The few data available suggest that the AQ adverse events are drug dose dependent (Hatton 
et al., 1986)(Cairns et a., 2010). Although drug associated severe and lethal reactions have not 
been generally observed in AQ regimens for the treatment of uncomplicated malaria 
(Olliaro et al., 1996)(Olliaro and Mussano, 2003), mild events are relatively frequent, being a 
threat for full regimen compliance (e.g. Gerstl et al., 2010), leading to incomplete cure and 
potential selection of resistant parasites. This effect can be decreased through genetic 
evidence-based adjustment of the dose, at a personalized level.  
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In addition, the knowledge of the frequencies of rare genetic variants associated with 
documented AQ-driven adverse events in certain ethnic groups and regions under AQ 
exposure can be useful as a pharmacovigilance tool. As an example, and taking in account 
the surpassing of a specific (evidence-based) threshold of allele frequency, the use of 
alternative first line ACTs (e.g aminoalcohol quinoline based, as artemether-lumefantrine) 
for those regions could be decided. Such type of measures - although not totally preventing - 
have the potential of decreasing the occurrence of serious events. 
It should be noted that such a population pharmacogenetics approach can be of great 
importance: the effect of fatal adverse events in the public opinion can be very significant, 
especially after the 1990s temporary withdrawal of AQ from the WHO list of recommended 
antimalarials. Such dramatic events - in particular involving the typical children under five - 
could lead to a further mistrust of the public about a drug that is pivotal in a large number 
of national malaria control programmes. 
5. The main players of AQ disposition 
As previously mentioned, upon oral absorption AQ is readily metabolized towards the 
pharmacologically active DEAQ. This biotransformation occurs mostly in the liver and is 
almost exclusively performed by the cytochrome P450 (CYP) 2C8 (Li et al., 2002). The high 
specificity of CYP2C8 for this reaction has even led to the proposal of AQ as a specific probe 
drug for this P450 isoform (Walsky et al., 2004). Besides this main step, other putative AQ 
metabolites have been proposed and at least partially confirmed (figure 1). These include 2-
hydroxy-DEAQ (Churchill et al., 1985), N-Bis-DEAQ (Mount et al., 1986) and M2, the latter 
initially detected in the microsome-based seminal studies of Li et al (2002), and recently 
confirmed through in vitro electrochemical approaches (Johansson et al., 2009). A fraction of 
DEAQ itself is believed to also be transformed in 2-hydroxy-DEAQ through P450 action. 
Several of these post-CYP2C8 action steps are catalyzed by members of the CYP1 sub-family 
(Li et al., 2002)(Gil and Gil-Berglund, 2007)(Johansson et al., 2009). 
Most importantly, both AQ and DEAQ are able to generate the highly reactive quinone-
imine (QI) metabolite responsible for the described serious side affects of AQ therapies. 
DEAQ is considered less prone to create QIs (Tingle et al., 1995), reinforcing the action of 
CYP2C8 over AQ as a protective event. The generation of these compounds has been 
previously proposed to occur spontaneously, but recent investigations have pointed to a 
fundamental role of CYP1A1 and CYP1B1 as well as the family of myeloperoxidases in the 
process. In this processes, the M2 metabolite initially identified by Li et al. has been 
proposed to be a central player in the generation of the toxic QIs (Johansson et al., 2009). 
Taking in account the fact that these species are most likely short-lived, it is expected that 
the enzymes involved in its generation will be present in the location of its toxic action. 
Suggestively, CYP1A1 and CYP1B1 are essentially extra-hepatic P450 isoforms, with 
confirmed expression in several blood cell types (e.g. leukocyes)(Furukawa et al., 2004), the 
most frequent location for these fatal toxicities (neutropenia). 
Scarce information is available concerning other ADME phases in AQ metabolism. The 
analysis of QI adducts in animal models have pointed for the presence of glutathione 
conjugates, although no specific isoform has ever been determined (Masubuchi et al., 2007). 
The potential production of phase II metabolites further points to the likely involvement of 
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phase III (transport) systems. The most common phase III glutathione conjugate 
transporters are the members of the ATP binding cassette (ABC) superfamily of proteins, 
and more specifically of the ABCC (also referred as MRP) type of transporters.  
A summarized proposal of the complex metabolism of AQ is presented in figure 1. 
 
 
Abbreviations - 1A1: CYP1A1; 1B1: CYP1B1; DEAQ:desethylAQ; QI: quinoneimine;  
N-bis DEAQ: bis-desethylAQ; C8: compound 8; C9: compound 9; C10: compound 10;  
QI-GS: quinoneimine-glutathione conjugates; GST: glutathione S-transferase;  
MRPs: multidrug resistance proteins.  
Fig. 1. The metabolism of AQ. Although the main biotransformation in this process is the 
synthesis of DEAQ, a constellation of minor – but most likely non-negligible – metabolites 
have been proposed to result in parallel (Churchill et al., 1985)(Mount et al., 1986)(Li et al., 
2002). Most importantly, events leading to the formation of the toxic QIs, involving both AQ 
and DEAQ are included among them. The presented scheme represents a summary of the 
available data from in vitro studies with microsomes, animal models, the few available 
human in vivo data, as well as the most recent information utilizing electrochemical 
approaches to simulate drug oxidation in vitro (Harrison et al., 1992)(Jewell et al., 
1995)(Tingle et al., 1995)(Naisbitt et al., 1997)(Li et al., 2002)(Johansson et al., 2009). 
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The previously identified M2 metabolite (Li et al., 2002) seems to be a central component in 
the generation of the QIs from both AQ and DEAQ, with CYP1A1 and CYP1B1 being the 
main enzymes involved in the process (Johansson et al., 2009). The QIs have been proposed 
to result from the action of myeloperoxidases, an event that is herein tentatively proposed to 
involve the M2 metabolite, although a direct action of these enzymes in both AQ and DEAQ 
cannot be disregarded. 
In vitro electrochemical approaches have generated a number of putative compounds, the 
most relevant being indicated here (C8, C9 and C10). This complex of compounds, due to its 
expected hydroxylated structures has been proposed to most likely represent the previously 
reported 2-hydroxy-DEAQ (Churchill et al., 1985). 
6. The pharmacogenetics of AQ metabolism 
As described, based on current knowledge, three main drug metabolizing enzymes are 
involved in the biotransformation of AQ: CYP2C8 (the main one), CYP1A1 and CYP1B1. All 
of them harbour significant genetic polymorphisms, some with marked effects in the 
catalytic activities of the respectively coded proteins. 
6.1 CYP2C8  
The CYP2C8 comprises nine exons. 14 alleles have been annotated in the gene coding for 
this 490 amino acid enzyme (http://www.cypalleles.ki.se/cyp2c8.htm), most of them rare. 
Apart from the most prevalent alleles, 2C8*1 (wild type), 2C8*2, 2C8*3, and 2C8*4, the 
majority of the remaining ones (2C8*5 - 2C8*12, see figure 2) have been identified only in the 
Japanese population (Soyama et al., 2001)(Nakajima et al., 2003). Few works have evaluated 
the presence of these minor alleles in other regions (Cavaco et al., 2006)(Suarez-Kurtz  
et al., 2010), although the output of large consortium projects (e.g. HapMap, 
www.sanger.ac.uk/resources/downloads/human/hapmap3.html) supports the view of 
these alleles being specific among the Japanese. On the other hand, 2C8*2, 2C8*3 and 2C8*4 
are rare in this population. (Nakajima et al., 2003)(table 1). 
African settings represent the major context where AQ therapy is practiced, both in 
combination with artesunate or sulfadoxine-pyrimethamine. The first CYP2C8 
pharmacogenetic study in endemic African populations was performed in East African 
populations, in the islands of Zanzibar (Cavaco et al., 2005)(table 1). In this population all the 
most studied mutant alleles, namely 2C8*2, 2C8*3 and 2C8*4, were detected.  Further studies 
in other regions of the continent have confirmed 2C8*2 as the main allele among the native 
populations (see table 1). Interestingly, outside Zanzibar, 2C8*3 (when found) has been 
documented at lower frequencies, while 2C8*4 has not been detected at all. These results 
point to the populations of Zanzibar as somewhat particular, perhaps due to the 
historical/migration influences from the Arabian Peninsula (Low and Smith, 1976).  
The data from native African populations was consistent with previous reports in African-
American, where the 2C8*2 allele represents the main mutant allele in Black populations 
(table 1), with the non-active 2C8*3 mostly present among Caucasians (Cavaco et al., 2006). 
A number of in vitro studies have been performed to characterize the phenotypic effect of 
the CYP2C8 polymorphisms. 
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Region (n*) 2C8*2 2C8*3 2C8*4 Reference 
     
Zanzibar (Unguja and Pemba)(n= 165) 13.9% 2.1% 0.6% Cavaco et al., 2005 
Ghana (Accra)(n= 204) 17.9% 0% 0% Kudzi et al., 2009 
Ghana (n= 92) 17.9% n/ta n/ta Adjei et al., 2008 
Ghana (Tamale) (n= 200) 16.8% 0.0% 0.0% Rower et al., 2005 
Burkina Faso (Bobo-Dioulasso) (n=275) 11.5% 0.4% n/t Parikh et al., 2007 
     
Southern India (n=245) 0.8% 2.9% n/t Arun Kumar et al., 2011 
Malaysiab (n= 57) 0.8% 1.2% 0% Muthiah et al., 2005 
South East Asia (n= 20) c 0.0% 5.0% 0% Solus et al, 2004 
     
Papua-New Guinea (Madang) (n = 305) 0% 0% 0% Hombhanje et al., 2005 
     
Brazil (scattered regions)(n= 1034)d 6.4% 8.6% 3.4% Suarez-Kurtz et al., 2010 
*number of subjects analysed; n/t (non tested) 
a Any 2C8*3 or 2C8*4 alleles present confounded in the 2C8*1 group. 
b Indian ethnic group 
c Derived from a commercial repository – no specific origin disclosed. 
d Ethnically mixed populations, originated from several scattered regions of the country. The sample is 
claimed by the authors to be representative of the present day Brazilian population; when considering self-
reporting ethnic origin, the 2C8*3 frequency increased among “White” subjects, while the *2 among “Black” 
individuals. 
(note: this compilation is intended to be a representative sample of the published information and not an 
exhaustive collection of the available data) 
Abbreviation – CYP2C8: 2C8 
Table 1. CYP2C8 main allele frequencies in populations from malaria endemic regions 
(Africa, Asia, Oceania and South America).  
The CYP2C8*2 allele is characterized by the presence of an I269F SNP. Quantitative 
HPLC/UV analysis of the DEAQ resulting from in vitro incubations of recombinant 
CYP2C8*2 enzyme with AQ pointed to a significant decrease of approximately 30% in the 
Vmax, (maximum substrate transformation rate) as compared with the wild-type (2C8*1) 
reference (0.16 ± 0.06 µmol/min/µmol P450 vs 0.23 ± 0.09 µmol/min/µmol P450).  
In parallel, the mutant allele was associated with a three-fold increase in its Km (substrate 
concentration at which the reaction reaches half of the Vmax value) (2.55 ± 1.06 µM vs  
0.81 ± 0.23 µM) (Parikh et al., 2007). This decreased performance was reflected in a 
significantly lower intrinsic clearance (Vmax/Km) of AQ (2C8*2: 0.05 l/min/µmol P450 vs 
2C8*1: 0.30 l/min/µmol P450). As for the CYP2C8*3, the presence of the two linked 
mutations characterizing this protein (R139K and R399K) had a marked effect on its catalytic 
capacities, with no AQ metabolism detected at any of the tested substrate concentrations 
(Parikh et al., 2007). It was concluded that the 2C8*3 protein has very low AQ metabolism 
activity. These results obtained with AQ are supported by data from previous studies using 
the CYP2C8 probe drug paclitaxel (Dai et al., 2001).  
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As for 2C8*4, in vitro experiments by Singh et al. have reported this protein as having a 10 
fold decrease in paclitaxel 6-alpha hydroxylase activity. The associated SNP (I264M, see 
figure 2) was proposed to affect heme insertion and the correct folding of the protein (Singh 
et al., 2008). It is expectable that this also represents a low activity allele as for the 
biotransformation of amodiaquine. 
More recently, Gao and collaborators performed tests based on the heterologous expression 
of 2C8*2, 2C8*3 and 2C8*4 in Saccharomyces cerevisae. Microsomes prepared from the 
transfected yeast cells were incubated with different concentrations of AQ. The experiments 
showed a decrease in the overall activity of the mutant alleles towards ~ 45-75% of the wild 
type values (Gao et al., 2010). The reasons behind the observed large differences in the 
capacities of these alleles between the microsome based systems and the in vitro based ones 
(i.e. reconstituted protein) are not fully clear. 
Some of the remaining minor alleles have been studied in some detail in Japan. The 2C8*5 
allele carries a 475delA mutation causing a frameshift effect leading to a premature 
translation termination at residue 177, and hence no functional protein (Soyama et al., 2002). 
Using microsomes obtained from CYP2C8 transfected COS-1 cells, the 2C8*6, 2C8*9 and 
2C8*10 proteins were shown not to significantly differ from the wild type (2C8*1) on 
paclitaxel 6-alpha hydroxylase activity. As for 2C8*8, this allele showed more than ten fold 
decrease in catalytic activity, associated with a less stable protein. As expected, 2C8*7 – 
involving the introduction of a translational stop codon - had no detectable enzyme activity 
(Hichiya et al., 2005). Finally, Hanioka and collaborators have recently used the same yeast 
system for testing the 2C8*13 and 2C8*14 alleles. While 2C8*13 did not show significant 
differences in Vmax and Km for paclitaxel 6-alpha hydroxylation as compared with 2C8*1, 
2C8*14 showed a 3 fold higher Km, albeit with no changes in the Vmax. 
A summary of relevant CYP2C8 SNPs and the associated phenotype characteristics is 
presented in figure 2. 
In vivo, there is limited information on the impact of CYP2C8 polymorphisms in AQ 
therapy, both in terms of efficacy and risk of adverse events. 
Parikh and collaborators have performed a retrospective analysis of an AQ monotherapy 
efficacy trial searching for in vivo phenotype/2C8 genotype associations (Parikh et al., 2007). 
The study involved 275 uncomplicated malaria patients from the region of Bobo-Dioulasso, 
southwest Burkina Faso. No associations were found between the clinical success of AQ 
therapy and the presence of minor CYP2C8 alleles (2C8*2 and 2C8*3). This is probably due 
to the fact that DEAQ, the main AQ metabolite, also represents a fully active antimalarial 
entity, i.e. enhanced AQ metabolism does not lead to an inactive metabolite that would 
decrease the clinical (pharmacodynamic) success of the therapy. More importantly, Parikh et 
al found a positive correlation between harbouring a 2C8*2 allele and events of mild side 
effects, mainly abdominal pain (self reported): 52% of occurrences among the 2C8*2 carriers 
versus 30% for the 2C8*1/*1 subjects. This is until now the only reported association between 
the patient CYP2C8 status and effects of AQ therapy. Another trial, performed in Ghana did 
not report such an association (Adjei et al., 2008). It also did not find clear associations 
between the pharmacokinetic parameters of AQ and the presence of less active alleles, 
although a trend for decreased DEAQ plasma concentrations among the 2C8*2 carriers was 
noted. It must be noted however, that the smaller size of this study (n=92) might have 
prevented the detection of such associations.  
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These are the only two published studies exploring the impact of the CYP2C8 
polymorphism in AQ based therapies, while near 100 million treatments performed in the 
last five years (WHO, 2010). It is evident that there is an urgent need of further research in 
this area, in order to guarantee the longest “useful life” for this drug, presently a cornerstone 
in the global control of malaria. 
6.2 CYP1A1  
CYP1A1 represents a 512 amino acid cytochrome P450 enzyme mainly expressed in extra-
hepatic tissues, including the lungs (Willey et al., 1997), intestine (Paine et al., 1999)(Paine et 
al., 2006), placenta (Hakkola et al., 1996) and, importantly, lymphocytes (Dey et al., 2001, van 
Duursen et al., 2005). It is usually present at low constitutive baseline levels. The gene is 
readily inducible through the AHR (Aryl Hidrocarbon Receptor) regulatory pathway, 
typically by exposure to PAHs (polycyclic aromatic hydrocarbons, e.g. components of 
tobacco smoke). Upon induction, CYP1A1 can also be found in the liver, where it usually is 
at very low (pre-induction) baseline levels. CYP1A1 is able to metabolize a number of 
clinically relevant drugs, including the calcium blocker flunarizine, the anticancer drug 
toremifene and the cardiovascular disease drug fluvastatin. Significant inter-individual 
variability in the elimination of these drugs has been described. This variability is probably 
of minor clinical concern, due to the non-hepatic patterns of expression of the gene. In the 
context of this review, the importance of CYP1A1 is mainly focused in its probable 
involvement in the generation of short lived but toxic AQ metabolites (Johansson et al., 
2009). 
The CYP1A1 gene (15q24.1) is organized in 7 exons. It harbours significant polymorphisms, 
comprising eleven established alleles (figure 2), as well as a number of SNPs with haplotype 
associations still to be assigned (http://www.cypalleles.ki.se/cyp1a1.htm). A significant 
portion of the non-synonymous polymorphisms is concentrated at exon 7 (figure 2)(table 2).  
The CYP1A1*2 allele has been documented in vitro to represent a more drug responsive gene 
upon exposure to the prototype inducer 2,3,7,8-tetrachlorodibenzo-para-dioxin 
(TCDD)(studies with the 1A1*2A and 1A1*2B haplotypes)(Spurr et al., 1987)(Landi et al., 
1994). Also, at least in the case of 1A1*2B and 1A1*2C, this allele was shown to code for more 
active enzymes (Cosma et al., 1993). The increased transcriptional response is related to the 
presence of a T3801C transition in the gene’s 3’ UTR, while the referred enhanced enzymatic 
activity (reflected specifically in an increased Vmax) is linked with a non-synonymous I462V 
SNP at exon 7 (Cosma et al., 1993). This enhanced activity of the proteins harbouring 462V 
(1A1*2B and 1A1*2C) was also confirmed in terms of estrone and 17 ß-estradiol 2-
hydroxylation, as a 5-10 fold increase in comparison to the wild type (Kisselev et al., 2005).    
The T461N SNP (defining 1A1*4) was shown not to alter significantly the behaviour of its 
coded enzyme (Kisselev et al., 2005). As for the 3’ UTR T3204C transition defining the 1A1*3 
allele (proposed to be specific of African populations) it does not seem to influence the levels 
of CYP1A1 expression (Smart and Daly, 2000). 1A1*7 represents a frameshift mutation 
leading to the generation of a stop codon and hence precluding the production of an active 
enzyme. Finally, alleles 1A1*8 (T448N), 1A1*9 (R464C) and 1A1*10 (R477W) carry non-
synonymous SNPs located close to the protein heme binding protein, and are hence 
expected to affect the activity of the enzyme (Saito et al., 2003). 
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Region (n*) 1A1*2 1A1*7 1A1*3 1A1*4 Reference 
      
Namibiaa (n= 134) 14.9%b n/t n/t n/t Fujihara et al., 2009 
Southwest Libya (El Awaynat 
and Tahala)c (n=129) 
6.5%d n/t 0% 18.1% 
Martinez-Labarga et 
al., 2007 
Midwest and Southeast Nigeria 
(n= 250) 
24.2%e n/t 13% 0% Okobia et al., 2005 
South Africaf (n= 96) 0% g n/t n/t n/t Dandara et al., 2002 
Zimbabwe  (n= 148) 0% g n/t n/t n/t Dandara et al., 2002 
Tanzania (n= 114) 1.3% g n/t n/t n/t Dandara et al., 2002 
Mali (n=116) 24.0% g n/t n/t n/t Garte et al., 1998 
      
East India (Chennai) (n=150) 33% g n/t n/t n/t Suneetha et al., 2011 
Southwest India (Kerala)  
(n = 146) 
20.9% n/t n/t n/t Sreeja et al., 2005 
Northern India (Delhi) (n= 309) 71.4%h n/t n/t 0% Kumar et al., 2010 
Northern Thailand 
(Lampang)(n= 287) 
84.9%h,i n/t n/t n/t Pisani et al., 2006 
China (Peking)(n= 284)j 28.2%h n/t n/t 0% Zhang et al., 2010 
* number of subjects analyzed; n/t: not tested 
a Bantu (Ocambo) ethnicity 
b T3798C tested, defining the presence of 1A1*2A or 1A1*2B. As the I462V was not determined (1A1*2C 
contribution not included) it is not possible to distinguish between these two forms. 
c Although these are regions not directly affected by malaria, the nomadic characteristics of the Tuareg 
populations under study puts them in risk when travelling to sub-Saharan areas (e.g. Northern Mali, 
Mauritania) 
d 1A1*2A= 4.5%, 1A1*2B= 0.2%, 1A1*2C=1.8% 
e 1A1*2A= 24%, 1A1*2C= 0.2%. Data on 1A1*2B not available. 
f Venda ethnicity 
g Only T3798C tested, so the data should be considered as the result of the 1A1*2A + 1A1*2B composite. 
h T3798C and I462V tested but no information on the composite of the two giving rise to *2B 
i 286 subjects analysed for 1A1*2A 
j Only the I462V analysed so 1A1*2A not included and 1A1*2B contribution not available 
(note: this compilation is intended to be a representative sample of the published information and not an 
exhaustive collection of the available data). 
Abbreviation - CYP1A1: 1A1 
Table 2. CYP1A1 allele frequencies of population from malaria affected regions of Africa and 
Asia. 
6.3 CYP1B1 
Similarly to CYP1A1, the expression of the CYP1B1 isoform is also predominantly extra-
hepatic, including peripheral blood cells (Hanaoka et al., 2002)(Furukawa et al., 2004), and it 
is inducible by exposure to several xenobiotics, namely PAHs (Nebert et al., 2004). 
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Null alleles are rare in the general population. Most were identified among patients with 
glaucoma, for which these alleles are an established risk factor (Stoilov et al., 1998), and are 
not a major concern in the context of this review. The main polymorphic positions in this 
gene are summarized in figure 2. 
The functional consequence of the major CYP1B1 alleles has been studied in vitro upon 
heterologous expression in E. coli and the quantification of the enzyme’s capacity of 
catalyzing the 4- and 2- hydroxylation of estradiol. The introduction of the R48G, A119S and 
N453S SNPs did not significantly change the Vmax and Km of the resulting proteins, as 
compared with the wild type (1B1*1) (Li et al., 2000). The L432V SNP was on the other hand 
associated increased of circa 3 fold in the Km. Later works using Saccaromyces cervisae 
heterologous expression systems supported the view of L432V carrier proteins as less active 
(>Km values <Vmax values). Interestingly, in these works this effect was only observed in the 
context of a SNP haplotype including other polymorphic positions (R48G + A119S + 
L432V)(Aklillu et al., 2002). Finally, several minor allele of this SNP (present in the 1B1*3, 
1B1*5, 1B1*6 and 1B1*7 alleles) have been proposed as associated with a transcriptionaly less 
active gene (Helmig et al., 2009, 2010). 
Presently there is still scarce information available concerning the CYP1B1 allele frequencies 
in populations living in malaria regions (table 3). 
 
Region (n*) 1B1*2 1B1*3 1B1*4 1B1*5 1B1*6 1B1*7 Reference 
        
Ethiopia (Adis Ababa) 
(n=150) 
36.7% 39.0% 2.0% 0.7% 6.3% 7.0% 
Aklillu et al., 
2002 
        
North India (Lucknow) 
(n=200) 
33.0% 21.3% 18.3% n/t n/t n/t Shah et al., 2008 
South Central Chin 
(Chengdu) (N= 400a) 
n/t 57.5%b n/t n/t n/t n/t Wang et al., 2011 
Northeast China (Nanjing) 
(N= 227) 
n/t 15.1%c n/t n/t n/t n/t Liang et al., 2005 
* number of subjects analyzed; n/t: not tested. 
a Only women were included in the study. 
b Only the L432V SNP was analysed, meaning that the declared frequency for 1B1*3, also is likely to 
include also the 1B1*5, 1B1*6 and 1B1*7 alleles. 
c Only women included in the study. The sole analysis of the A119S does not distinguish between the 
1B1*2, 1B1*6 and 1B1*7. 
(note: this compilation is intended to be a representative sample of the published information and not an 
exhaustive collection of the available data). 
Abbreviation – CYP1B1: 1B1 








a Haplotype not determined yet (reference SNP: rs11572102, NCBI 
(http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=11572102);  
b Discovered by Soyama et al., 2001 and phenotypically characterized by reduced catalytic activity 
(Soyama et al., 2002)(Jiang et al., 2011). 
c The colour code was herein applied according to the data of Aklillu et al. (2002). It is to note that initial 
studies by Li et al (2000) noticed a significant decrease in the activity of the protein. 
Fig. 2. Genetic diversity of CYP2C8, CYP1A1 and CYP1B1, the main polymorphic genes 
involved in AQ phase I metabolism. Although the gene structures are represented, the 
locations of established polymorphisms are presented using the amino acid nomenclature as 
this is more relevant for the present review. For the sake of clarity, only the most studied 
alleles, with established haplotype structures are presented. Alleles shown in red color 
indicate protein products reported to be less active than the reference wild type (*1). Alleles 
in green do not have a significant differences as compared with *1, whereas alleles flagged 
in blue have higher activity than the wild type. For alleles in black there is currently no 
experimental information available. In the case of the CYP1B1 the use of the colors is restricted 
to alleles (and not SNPs) due to the availability of haplotype data (Akillilu et al., 2002). 
7. The CYP2C8, CYP1A1, CYP1B1 trio - Potential implications 
In terms of therapeutic efficacy, since DEAQ is a powerful and clinically valuable 
antimalarial, variations in the CYP2C8 enzymatic capacity are not expected to have 
significant pharmacodynamic consequences. As mentioned, this expectation is in line with 
observations by Parikh et al in Burkina-Faso, where the presence of CYP2C8*2 did not 
influence the treatment outcome of AQ monotherapy. On the other hand, pharmacogenetics 
might be of particular importance in the identification of individuals in higher risk of 
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developing AQ-related adverse events. This is supported by the observation in the same 
study that the presence of CYP2C8*2 (still an allele associated with significant catalytic 
capacity, as compared with the much less functional 2C8*3 and 2C8*4) can influence the 
individual risk for mild adverse events, even in heterozygous form could. 
Recently in vitro evidence was published supporting the involvement of CYP1A1 and 
CYP1B1 in the generation of toxic QIs from AQ (and DEAQ) (Johansson et al., 2009). This 
confirmation of preliminarily reports (Li et al., 2002, I. Cavaco, Universidade do Algarve, 
unpublished) has opened a new perspective towards individualization of AQ therapy to 
minimize adverse events. In fact, contrarily to the previous view of a spontaneous formation 
of QIs (Tingle et al., 1995), the involvement of these polymorphic P450s reinforces a broader 
genetic basis for the phenomenon, which was until now almost exclusively focused on 
CYP2C8 (Cavaco et al., 2005). The now recognized more extensive genetic background of AQ 
adverse drug events underlines the importance of individualized medicine and the 
possibility to identify appropriate molecular markers for predicting response to 
treatment/risk of adverse reactions. 
With this new data, the hypothetical characterization of the sub-group of subjects in higher 
risk is starting to emerge. The first assumption is that such individuals carry a deficient 
CYP2C8 gene (2C8*2, ideally the very low active 2C8*3 or 2C8*4), allowing an extended half-
life for AQ (Parikh et al., 2007). This will probably represent the group with T1/2 values >12 
hours (Giao and de Vries, 2001), as well as the observed outliers showing very long 
exposure to the drug (Winstanley et al., 1987). With this increased pool of circulating AQ (as 
previously referred, a compound more prone than DEAQ for the formation of the QI 
reactive species (Tingle et al., 1995)), the drug will have higher chances to be extra-
hepatically catalysed by CYP1A1 and CYP1B1 - both present in leucocytes, where AQ tends 
to accumulate (Naisbitt et al., 1997). The rate of QI formation is expected to be further 
enhanced if particularly efficient versions of CYP1A1 and CYP1B1 are present, namely the 
CYP1A1*2, and CYP1B1*1 (wild type) enzymes. The resulting enhanced generation of QIs in 
the blood, coupled with the referred low CYP2C8 activity could be the basis of the 
previously documented AQ induced severe agranulocytosis. 
Interestingly, the involvement of CYP1A1 and CYP1B1 has another implication: In adult 
patients whom are smokers, both genes are likely to be induced by the polycyclic aromatic 
hydrocarbons (PAHs), which is present in tobacco smoke, through the activation of the aryl 
hydrocarbon receptor (AhR) based pathway (Nebert et al., 2004). This will also lead to the 
expression of these genes in the liver, another location for fatal AQ induced toxicity. Adult 
patients are characteristic of areas of low transmission, where the low exposure during the 
earlier periods of life does not allow the development of natural immunity to the diseases as 
an adult (premunition, frequent in the African continent (Struik and Riley, 2004)). Such 
malaria settings are the norm in South America regions, where populations carry a 
significant Caucasian genetic background and hence, an expected high frequency of the 
CYP2C8*3 allele. This has been confirmed in a pilot screening study conducted in 
populations of Northern Colombia where the frequency of this allele was ca. 7% (I. Cavaco, 
Universidade do Algarve, unpublished). In such areas it would be worthwhile to conduct 
trials in order to understand the influence that tobacco habits might have in the incidence of 
mild and serious adverse events associated to AQ treatments. Its connection with the 
CYP2C8/CYP1A1/CYP1B1 polymorphic set would be of interest, e.g. identifying patients 
that should be advised to decrease their smoking rate in time periods relevant for treatment. 
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Currently the epicentre of AQ use is in the Africa where the 2C8*3 and 2C8*4 alleles seem 
to be rare in the native populations. However, this observation is based on a very limited 
number of small studies, surely not representative of the overall population of the 
continent, the genetically most diverse on the planet (Lambert and Tishkoff, 2009). In 
addition, even though these alleles are considered “rare”, one has to take into account the 
dimensions of the malaria control challenge. A frequency of 1% for the 2C8*3 allele in a 
universe of at least 20 million AS-AQ treatments performed per year (WHO, 2010 - just 
the public sector, and not counting with the SP-AQ combination), would translate to 
~2,000 homozygotes for 2C8*3 patients per year. Secondly, AQ resistance, although still 
not globally prevalent, is slowly increasing (Holmgren et al., 2006). Its potential expansion 
might lead to the need for increased drug dosage, as previously decided in the cases of 
CQ (Peters, 1970)(Ursing et al., 2009, 2011) and mefloquine (Carrara et al., 2009). By 
approaching the top of the AQ therapeutic window, the risks of toxicity will increase to a 
point when serious side effects might be “under the reach” of the less compromised 2C8*2 
allele. 
8. The CYP2C8, CYP1A1, CYP1B1 trio  - Potential applications 
Pharmacogenetic markers in AQ therapies are expected to serve mostly as surveillance tools 
of adverse events of the drug. The identification of individuals with a genetic predisposition 
to AQ side effects (e.g. a 2C8*2/*2 carrier) would prompt the direct diversion of this patient 
towards different doses or the available second line treatment (e.g. artemether-lumefantrine 
or artesunate-mefloquine).  
An alternative therapeutic strategy could be the use of a more personalized (i.e. more 
optimized) AQ dosing, with values below the conventional 10 mg/Kg, or through a 
different regimen schedule. As the incidence of side effects is dose dependent (Cairns et al., 
2010), individualized treatment would be expected to reduce those events. The success of 
such strategies could boost the patient’s (and specially their guardians) trust on the 
treatment, leading to increased compliance to the full dosing regimen. This effect has been 
witnessed with the anti-HIV drug abacavir, where the application of pharmacogenetic 
testing has increased the use of this drug (Ingelman-Sundberg, 2008)(Chaponda and 
Pirmohamed, 2011). Unfortunately, clinical studies to support future guidelines concerning 
the ideal dose for certain pharmacogenetic configurations are clearly missing. Initiatives to 
address this issue, such as the WANECAM Consortium in East Africa, are presently under 
way (see: www.edctp.org/annualreport2010/EDCTP_Annual_Report_2010_English.pdf). 
The application of pharmacogenetics can contribute to an extended useful life of AQ, 
through its better use. Chemotherapy represents a central strategy for the long desired 
global elimination of the disease (malERA Consultative Group on Drugs, 2011), an event 
fundamental for the social-economical development of the Developing World. AQ is one of 
its central tools in these efforts (Bhattarai et al., 2007) – its safer and consequently longer use 
can be pivotal in this process.  
But, although promising, are these pharmacogenetic applications possible in the present 
context of the Developing World health systems? In short, no. The prices of 
pharmacogenetic testing are still very high, totally eclipsing the costs of the therapy itself. 
A complete AS-AQ treatment in Africa will cost below US$5, already taking in 
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consideration a price of US$ 0.5-1 for the Coarsucam®/Winthorp® fixed combination 
supplied by Sanofi-Aventis (Shillcutt et al., 2008). As previously calculated (Ferreira et al., 
2008), the analysis of the CYP2C8*3 allele alone will demand a minimum of US$50, taking 
in account the local costs of human resources and reagents. An upgrade towards the 
determination of the CYP2C8*2 allele, plus CYP1B1*2 and CYP1A1*2, would increase the 
financial burden per patients to values well above US$ 100 per patient, the equivalent of 
more than one hundred treatments. Besides, the maintenance of a system with the 
required quality standards for molecular diagnostic analysis would be in the order of 
many tens of thousands of US$/year. All this has to be put further in the context of 
populations with an available national health expenditure of less then 
US$25/year/citizen. The pharmacogenetic testing for AQ therapy alone would consume 
the funds of four years of health care. 
So, what is the translational value of pharmacogenetics in such scenario? In fact there are at 
least two venues of development. 
The first is what will be called here as “population pharmacogenetics”. As explained, the 
application of individual dose adjusted AQ therapies based on pharmacogenetics is 
essentially not viable. Alternatively, the study of the allele frequencies of pivotal markers 
in representative samples of specific populations/regions can be of considerable interest 
for national and regional health programmes, particularly in countries with a rich ethnic 
diversity, as it is frequent in the African continent. This would define the populations 
where therapeutics based in AQ would be safe, and the ones where an alternative 
antimalarial (like artemether-lumefantrine) would be the better choice. In a way, it would 
be the equivalent of rationally deciding not to introduce AQ in Europe, due to the high 
prevalence of the CYP2C8*3 allele (Cavaco et al., 2006). Several malaria endemic countries 
have more than one first line recommended treatment (e.g. Burkina Faso, Mali, Colombia, 
Peru (http://www.who.int/malaria/publications/treatment-policies/en/index.html), 
having as such a start up capacity for implementing region-specific policies. Such a 
programme could be centralized taking advantage of pre-existing molecular technology 
facilities used e.g. for molecular parasitology. In this context it is worth mentioning that 
new techniques are surfacing for the extraction of DNA from Rapid Diagnostic Tests  
(P. Ferreira, Karolinska Institutet, pers. commun)(Alam et al., 2011). These can be further 
coupled with novel inexpensive amplification-free genotyping approaches (Aw et al., 
2011), allowing the ready molecular characterization of the patient in field settings.  
Such an application of pharmacogenetics would aid evidence-based decisions for optimized 
antimalarial use, at a population level. This would allow the use of safer ACT alternatives 
for the benefit of specific populations. 
The second venue has to do with the target country. Malaria is a significant public health 
concern in three of the “BRIC” emerging economies: Brazil, India and China. These large 
countries are rapidly developing economic capacity compatible with a first large scale 
application of personalised anti-infection therapies. In this context, it should be noted that 
the populations of Brazil and India (incidentally, the ones with larger malaria burden) have 
been shown to harbour non-negligible CYP2C8*3 frequencies (Arun Kumar et al., 
2011)(Suarez-Kurtz et al., 2010)(table 1). In these countries the resources for personalized 
medicine as previously described are potentially available. 
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Although tens of millions of AQ doses are prescribed per year, the knowledge of the 
pharmacogenetics of this drug is still limited. In particular, stronger in vivo 
phenotype/genotype associations are needed for the definition of genetic markers of AQ 
overexposure risk.  
This must be obtained through several venues. A basic need is the performance of clinical 
trials designed for the detection of adverse events, mild or eventually serious. These are 
needed to be relatively large (>500 subjects), due to the non-precise nature of the former (e.g. 
self reported abdominal pain in children under five), and the rarity of the latter. Such studies 
must include a long follow up for the detection of possible late onset events, as well as the 
reaction of the subject upon repetitive treatments. Also, the inclusion of full sequencing 
approaches in such reference studies would be fundamental, especially in cases of particularly 
relevant phenotypes. As previously mentioned, studies of this type are presently undergoing. 
Such trials will allow the establishment of better phenotype/genotype associations that can be 
further explored in the context of health structures integrated in national malaria programmes. 
In this second step, technologies like the DNA extraction from Rapid Diagnostic Test devices, 
coupled with novel simple genotyping methods with applications in the field can be used in 
order to further establish polymorphisms in CYP2C8, CYP1A1, CYP1B1 or other relevant 
genes (e.g. myeloperoxidases) as risk markers of AQ over-exposure. 
With true personalized medicine being presently out of reach in most malaria affected 
countries, population pharmacogenetics of such markers will supply information for the use 
of the best available chemotherapy option, at a public health level. An example of such 
application would be the use of an alternative second line treatment (e.g. artemether-
lumefantrine) as first liner for certain regions and/or populations of a country. Such a 
strategy would optimize the use of the available antimalarial arsenal in the national control 
programmes. A more personalized analysis could be potentially applied in the much less 
frequent (< 10%) situations of AS-AQ use as second liner.  
A population-based approach, as described, can offer true benefits for the optimization of 
national malaria treatment, in particular when integrated in malaria elimination efforts, where 
the maintenance of the useful life of well established and effective therapies is key. Once the 
incidence of malaria decreases, as for example witnessed in the Zanzibari islands (Bhattarai et 
al., 2007), countries will be able to start supporting more personalized application of 
pharmacogenetics. In conclusion, upon the solid establishment of pharmacogenetics markers, 
the success of their application at a population level can lay the basis for a future more 
personalized pharmacogenetics, once the countries would be able to finance it. By the same 
token, the Developing World would not be left behind in this area of translational medicine. 
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